Details for New Drug Application (NDA): 091417
✉ Email this page to a colleague
NDA 091417 describes RILUZOLE, which is a drug marketed by Alkem Labs Ltd, Apotex Corp, Daito Pharms Co Ltd, Glenmark Pharms Ltd, Impax Labs, Kenton, Mylan Pharms Inc, and Sun Pharm Inds Ltd, and is included in nine NDAs. It is available from six suppliers. Additional details are available on the RILUZOLE profile page.
The generic ingredient in RILUZOLE is riluzole. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the riluzole profile page.
The generic ingredient in RILUZOLE is riluzole. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the riluzole profile page.
Summary for 091417
| Tradename: | RILUZOLE |
| Applicant: | Sun Pharm Inds Ltd |
| Ingredient: | riluzole |
| Patents: | 0 |
Suppliers and Packaging for NDA: 091417
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| RILUZOLE | riluzole | TABLET;ORAL | 091417 | ANDA | Sun Pharmaceutical Industries, Inc. | 62756-538 | 62756-538-18 | 1000 TABLET, FILM COATED in 1 BOTTLE (62756-538-18) |
| RILUZOLE | riluzole | TABLET;ORAL | 091417 | ANDA | Sun Pharmaceutical Industries, Inc. | 62756-538 | 62756-538-83 | 30 TABLET, FILM COATED in 1 BOTTLE (62756-538-83) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Jun 18, 2013 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
